Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Peter Kier"'
Autor:
Angelika Reiner-Concin, Christian Sebesta, Wolfgang Hinterberger, Peter Zelenka, Reinhard Ruckser, Veronika Buxhofer-Ausch, Isabel Schmid, Emil Ogris, Georg Tatzreiter, Karl Heinz Habertheuer, Christoph Ausch, Walter Hruby, Margareta Hinterberger-Fischer, Peter Kier
Publikováno v:
European Journal of Haematology. 73:143-146
A 57-yr-old woman with multiple myeloma received an autologous tandem transplant at a 4-month interval. She was conditioned twice with 225 mg/m 2 melphalan. After the second transplant, interstitial pneumonitis (IP) ensued. The clinical course was li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8eb33a27ff04cc1b539cca0e61539c7c
https://doi.org/10.1111/j.1600-0609.2004.00276.x
https://doi.org/10.1111/j.1600-0609.2004.00276.x
Autor:
Peter Zelenka, Walter Hruby, Christian Sebesta, Wolfgang Hinterberger, Engelbert Knosp, Karl-Heinz Habertheuer, Stefan Dorner, Peter Kier, Georg Tatzreiter, Veronika Buxhofer, Reinhard Ruckser
Publikováno v:
European Journal of Haematology. 67:128-132
We describe in detail a 67-yr-old woman who was treated with a cytostatic combination chemotherapy for newly diagnosed common-acute lymphoblastic leukaemia. At the end of induction therapy, the patient acquired invasive mould infection affecting lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::191f1c045d8dcb95c63097dd4a3cfa3b
https://doi.org/10.1034/j.1600-0609.2001.t01-1-00461.x
https://doi.org/10.1034/j.1600-0609.2001.t01-1-00461.x
Publikováno v:
Blood. 79:1081-1086
Previously we observed that sera from recipients of allogeneic bone marrow transplants who developed extensive chronic graft-versus-host disease (GVHD) intensively stained the nucleolar region of target cells in indirect immunofluorescence microscopy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::804dd856a591f426f6951c42ccfe3252
https://doi.org/10.1182/blood.v79.4.1081.1081
https://doi.org/10.1182/blood.v79.4.1081.1081
Autor:
Veronika, Buxhofer-Ausch, Reinhard, Ruckser, Peter, Kier, Karl Heinz, Habertheuer, Peter, Zelenka, Georg, Tatzreiter, Christoph, Ausch, Isabel, Schmid, Walter, Hruby, Angelika, Reiner-Concin, Christian, Sebesta, Emil, Ogris, Margareta, Hinterberger-Fischer, Wolfgang, Hinterberger
Publikováno v:
European journal of haematology. 73(2)
A 57-yr-old woman with multiple myeloma received an autologous tandem transplant at a 4-month interval. She was conditioned twice with 225 mg/m2 melphalan. After the second transplant, interstitial pneumonitis (IP) ensued. The clinical course was lif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::38c81b4584ddcfe1076fcea39305d748
https://pubmed.ncbi.nlm.nih.gov/15245515
https://pubmed.ncbi.nlm.nih.gov/15245515
Autor:
Christian Sebesta, Wolfgang Hinterberger, Eva Maria Kittl, Kurt Bauer, Peter Kier, Sabine Selleny, Karl-Heinz Habertheuer, Michael Fangl, Emil Ogris, Margareta Hinterberger-Fischer, Alfons Schmid, Reinhard Ruckser
Publikováno v:
American journal of clinical oncology. 23(4)
Prolactin is a suspected promotor of breast cancer cell growth, and it shares pleiotropic immunoregulatory properties. We studied plasma prolactin and its drug-induced modulation in 20 women with breast cancer undergoing high-dose chemotherapy and au
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::720693a4456e54efc4071ddd07fba65e
https://pubmed.ncbi.nlm.nih.gov/10955855
https://pubmed.ncbi.nlm.nih.gov/10955855
Autor:
Veronika Buxhofer-Ausch, Karl-Heinz Habertheuer, Selma Hoenigschnabl, Christian Sebesta, Elvira Kitzweger, Georg Tatzreiter, Reinhard Ruckser, Peter Zelenka, Angelika Reiner-Concin, Peter Kier
Publikováno v:
Journal of Clinical Oncology. 30:e14087-e14087
e14087 Background: Immunotherapy in real-life, unselected patients with metastatic colorectal cancer (mCRC) was analyzed retrospectively at a single center in Austria. Methods: We have treated 137 mCRC patients with at least one antibody containing t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49d01bcde92925104dead8054db2d7e6
https://doi.org/10.1200/jco.2012.30.15_suppl.e14087
https://doi.org/10.1200/jco.2012.30.15_suppl.e14087
Autor:
Peter Kalhs, Klaus Lechner, Klaus Geissler, Paul A. Kyrle, Peter Kier, Christa Forstinger, Paul Knöbl
Publikováno v:
Annals of internal medicine. 117(3)
Excerpt Some patients with aplastic anemia show temporary improvements in hematopoiesis after monotherapy with hematopoietic growth factors (1-3), but those with severe cases rarely respond (4). In...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44e69b7b202808cce0a8d51a15f06479
https://pubmed.ncbi.nlm.nih.gov/1377461
https://pubmed.ncbi.nlm.nih.gov/1377461
Publikováno v:
ADP-Ribosylation Reactions ISBN: 9781461264569
Chronic graft-versus-host disease (c-GVHD), one of the major clinical complication of human allogeneic bone marrow transplantation has similarities with autoimmune diseases such as systemic lupus erythematosus or scleroderma (Ferrara and Deeg, 1991;S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9605c036daaaa7ac5d7027c21165fdee
https://doi.org/10.1007/978-1-4419-8718-1_44
https://doi.org/10.1007/978-1-4419-8718-1_44
Publikováno v:
Annals of internal medicine. 113(10)
Study Objective:To evaluate splenic function in bone marrow transplant recipients, with relation to chronic graft-versus-host disease and infections. Design:Survey, outpatients geographica...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03703e9e6698a79eb4d171e9b52a2885
https://pubmed.ncbi.nlm.nih.gov/2240887
https://pubmed.ncbi.nlm.nih.gov/2240887
Autor:
Stefan Hraby, Reinhard Ruckser, Elvira Kitzweger, Georg Tatzreiter, Karin Strecker, Veronika Buxhofer, Milos Hejtman, Wolfgang Hinterberger, Margarete Stampfl, Karl Heinz Habertheuer, Peter Kier
Publikováno v:
Blood. 110:4838-4838
Introduction: Lenalidomide (Revlimid®) plus dexamethasone therapy and single-agent bortezomib therapy are approved for the treatment of relapsed/refractory multiple myeloma (MM) patients. A recent phase II trial has shown activity of lenalidomide/bo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f5dccfe6db7b3ca57f87bbfff7d75b4
https://doi.org/10.1182/blood.v110.11.4838.4838
https://doi.org/10.1182/blood.v110.11.4838.4838